<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Esophageal brushing cytology (EBC) and gastroesophageal biopsy (GEB) are complementary procedures for the evaluation of gastroesophageal lesions that help guide surveillance and treatment </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The authors investigated loss of heterozygosity (LOH) of 17 microsatellite repeat markers near <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes in gastroesophageal lesions on 34 concomitant EBCs and GEBs </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The results indicated that there was progressive accumulation of LOHs toward <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>EBC samples a greater area than GEB, and more LOHs are detected by EBC than GEB </plain></SENT>
<SENT sid="4" pm="."><plain>The combination of cytomorphology and detection of LOHs can improve diagnostic accuracy and is a more useful methodology with which to evaluate gastroesophageal lesions than either EBC or GEB alone </plain></SENT>
<SENT sid="5" pm="."><plain>The authors also found that LOHs at 1p36, 9p21, and 17p13 may play an important role in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> (BE), LOHs at 10q23, 17p13, and 17q12 in low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (LGD), LOHs at 5q23 and 17q21 in high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD), and LOHs at 5q23 and 21q22 in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Detection of LOHs targeting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes can be useful in evaluating gastroesophageal lesions, studying <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> of gastroesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and, in combination with EBC and GEB, determining surveillance for BE and LGD and/or treatment for HGD and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>